PMC:7228307 / 45239-45459 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"809","span":{"begin":160,"end":164},"obj":"Gene"},{"id":"810","span":{"begin":135,"end":139},"obj":"Gene"},{"id":"817","span":{"begin":14,"end":18},"obj":"Gene"},{"id":"835","span":{"begin":26,"end":31},"obj":"Mutation"},{"id":"849","span":{"begin":47,"end":52},"obj":"Mutation"},{"id":"853","span":{"begin":33,"end":38},"obj":"Mutation"},{"id":"854","span":{"begin":40,"end":45},"obj":"Mutation"},{"id":"856","span":{"begin":54,"end":59},"obj":"Mutation"},{"id":"857","span":{"begin":61,"end":66},"obj":"Mutation"},{"id":"858","span":{"begin":68,"end":73},"obj":"Mutation"}],"attributes":[{"id":"A809","pred":"tao:has_database_id","subj":"809","obj":"Gene:2213"},{"id":"A810","pred":"tao:has_database_id","subj":"810","obj":"Gene:2213"},{"id":"A817","pred":"tao:has_database_id","subj":"817","obj":"Gene:5133"},{"id":"A835","pred":"tao:has_standard_notation","subj":"835","obj":"rs1469294455"},{"id":"A849","pred":"tao:has_standard_notation","subj":"849","obj":"p.L235A"},{"id":"A853","pred":"tao:has_standard_notation","subj":"853","obj":"p.E233P"},{"id":"A854","pred":"tao:has_standard_notation","subj":"854","obj":"rs755807976"},{"id":"A856","pred":"tao:has_standard_notation","subj":"856","obj":"p.D265A"},{"id":"A857","pred":"tao:has_standard_notation","subj":"857","obj":"p.L309V"},{"id":"A858","pred":"tao:has_standard_notation","subj":"858","obj":"p.R409K"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T796","span":{"begin":135,"end":137},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T797","span":{"begin":160,"end":162},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T233","span":{"begin":14,"end":16},"obj":"Chemical"}],"attributes":[{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"809","span":{"begin":160,"end":164},"obj":"Gene"},{"id":"810","span":{"begin":135,"end":139},"obj":"Gene"},{"id":"817","span":{"begin":14,"end":18},"obj":"Gene"},{"id":"835","span":{"begin":26,"end":31},"obj":"Mutation"},{"id":"849","span":{"begin":47,"end":52},"obj":"Mutation"},{"id":"853","span":{"begin":33,"end":38},"obj":"Mutation"},{"id":"854","span":{"begin":40,"end":45},"obj":"Mutation"},{"id":"856","span":{"begin":54,"end":59},"obj":"Mutation"},{"id":"857","span":{"begin":61,"end":66},"obj":"Mutation"},{"id":"858","span":{"begin":68,"end":73},"obj":"Mutation"}],"attributes":[{"id":"A810","pred":"pubann:denotes","subj":"810","obj":"Gene:2213"},{"id":"A817","pred":"pubann:denotes","subj":"817","obj":"Gene:5133"},{"id":"A835","pred":"pubann:has_HGVS_notation","subj":"835","obj":"rs1469294455"},{"id":"A858","pred":"pubann:has_HGVS_notation","subj":"858","obj":"p.R409K"},{"id":"A857","pred":"pubann:has_HGVS_notation","subj":"857","obj":"p.L309V"},{"id":"A853","pred":"pubann:has_HGVS_notation","subj":"853","obj":"p.E233P"},{"id":"A856","pred":"pubann:has_HGVS_notation","subj":"856","obj":"p.D265A"},{"id":"A854","pred":"pubann:has_HGVS_notation","subj":"854","obj":"rs755807976"},{"id":"A849","pred":"pubann:has_HGVS_notation","subj":"849","obj":"p.L235A"},{"id":"A809","pred":"pubann:denotes","subj":"809","obj":"Gene:2213"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T262","span":{"begin":0,"end":220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T559","span":{"begin":14,"end":18},"obj":"Protein"}],"attributes":[{"id":"A559","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/Q7M4M5"},{"id":"A560","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/Q6NZ54"},{"id":"A561","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/Q3KQW2"},{"id":"A562","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/P18621"},{"id":"A563","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/J3QL51"},{"id":"A564","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/B5ME31"},{"id":"A565","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/B4E3C2"},{"id":"A566","pred":"uniprot_id","subj":"T559","obj":"https://www.uniprot.org/uniprot/B2R4H3"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T28","span":{"begin":201,"end":209},"obj":"Phenotype"}],"attributes":[{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-sentences","denotations":[{"id":"T262","span":{"begin":0,"end":220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T28","span":{"begin":201,"end":209},"obj":"Phenotype"}],"attributes":[{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III"}